Clinical trial
Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2
NCT00383604 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00383604 |
|---|---|
| Title | Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2 |
| Official title | Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2 |
| Lead sponsor | Stanford University, Other |
| Collaborators | California Breast Cancer Research Program |
| Status | Completed |
| Study type | Observational |
| Conditions | Lymphedema, Breast Cancer |
| Enrollment | 30 |
| Start date | Jul 1, 2005 |
| Primary completion | Mar 1, 2012 |
| Completion | Apr 1, 2012 |
| First posted | Oct 3, 2006 |
| Last update posted | May 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: